The US Approved an Alzheimer's Drug. Seven Patients Subsequently Died
Despite the known risks of patients experiencing life-threatening side effects, prescribing standards vary widely among medical centers.
Leqembi’s EU review drags on; Sanofi gets a new development head
The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...
Fierce Pharma9d
Eisai lays out road map to blockbuster sales projections for Leqembi's 'milestone' 2027 year
With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...
New Study Questions Effectiveness of Popular Alzheimer’s Drug Leqembi in Women
McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and ...
BioSpace8d
Eisai Lowers Sales Expectations for Leqembi Again, Citing Slow US Uptake
There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...
Rebecca Jones shares her Alzheimer's journey and hope found in new LEQEMBI treatment
Today on Living Oklahoma we were joined by Rebecca Jones.She spoke to Matt Stafford about here journey with Alzheimer's and ...
BioSpace6d
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
Eli Lilly's Alzheimer's drug rejected in Europe
The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...
Fierce Pharma6d
Eli Lilly's Alzheimer's contender Kisunla gets thumbs-down from EU regulators over safety concerns
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...
Biogen: Balancing Risks And Opportunities
Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...
Eli Lilly’s (LLY) Alzheimer’s Drug Is Rejected in Europe Over Safety Fears
A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...
The Boston Globe3d
The US approved an Alzheimer’s drug. Seven patients subsequently died.
Aaron is one of at least seven people who have died in the US from symptoms linked to the drug Leqembi over the past two years, according to a Bloomberg review of federal records obtained through ...